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Alzheimer’s disease (AD) is the sixth leading cause of death in the US.  Some 
researchers refer to AD as “Type III Diabetes” because of reported glucose metabolism 
dysfunction.  Preclinical studies suggest increasing insulin decreases AD pathology, although 
the mechanism remains unclear.  To sensitize insulin signaling, this study activated 
Peroxisome Proliferator-Activated Receptor Gamma using intranasal co-administration of 
pioglitazone (PGZ) and insulin.  This method targeted the site of action to reduce peripheral 
effects and to maximize impact in transgenic mice expressing AD pathology.  Data from 
GC-MS fluxomics analysis suggested that PGZ+Insulin increased glucose metabolism in the 
brain.  Immunohistochemistry with relevant antibodies was used to identify AD pathological 
markers in the subiculum, indicating that PGZ+Insulin decreased pathology compared to 
Insulin and Saline.  This suggests that increasing glucose uptake in the brain alleviated AD 
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 This thesis is submitted as part of the Gemstone program, a four-year 
interdisciplinary honors program at the University of Maryland.  In the Gemstone 
program, students create and complete their own research projects in teams led by a 
faculty member.  The purpose of this rigorous program is to allow students to develop 
the skills to research problems relevant to society, foster teamwork and leadership, 
and provide a supporting community of dedicated students.  
 Team Brain Blast is made up of 12 undergraduate students with majors 
ranging from International Business to Mechanical Engineering to Physiology and 
Neurobiology.  Dr. Kara Duffy serves as the team mentor and a researcher at the 






We were the last gemstone team of our cohort to receive a mentor because it 
was difficult to find someone who specialized in our research area of interest. 
Although he did not have much background in our research area, Dr. B stepped up 
and offered to be our mentor because he had had such a great experience mentoring a 
previous gemstone team, and was excited to learn along with us.  Dr. B was integral 
in the development of our project.  He was a brilliant scientist, excited to learn about 
a new area.  Beyond his intelligence, Dr. B was an incredible mentor figure, as well 
as friend, to each and every one of us.  He showed genuine care and interest in all of 
our lives, and loved to learn about our academic endeavors, as well as extracurricular 
interests.  He also liked to share gossip with us and we would often have to focus him 
at our meetings to talk about science.  It is clear that Dr. B made friends everywhere 
he went because many of his colleagues were happy to help our team. 
It was because of Dr. B that we were able to meet our current mentor Dr. Kara 
Duffy, who had agreed to be our team expert in the beginning stages of our project.  
In dealing with Dr. B’s passing, our team again found ourselves lucky enough to have 
someone step up and become our mentor even when the circumstances were not 
easy—and  for that, we are incredibly grateful to Kara.  We could not have achieved 
finishing our research without her or anyone else who had helped us along the way—
and the fact that so many of Dr. B’s colleagues had gone out of their way to help us 
after his passing is a true testament to his character and the genuine relationships he 
had with them. 
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In team meetings, we often reminisce about our memories with Dr. B, or ask 
“what would Dr. B think about this?”  It is clear that his presence remains all 
throughout our project, and for that, we dedicate our research to Dr. Brian Bequette. 
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Chapter 1: Introduction 
1.1  Problem Description and Motivation 
Alzheimer’s Disease (AD) is a major neurocognitive disorder (NCD) that 
progressively destroys memory and other cognitive functions.  AD was named after 
Dr. Alois Alzheimer, who first characterized the disease in 1906.  AD is the most 
common form of major NCD and currently impacts the lives of over five million 
Americans.  It is now the sixth leading cause of death in the United States, mostly 
affecting people 65 years of age and older (Alzheimer’s Association, 2015).  
Although there are pharmaceutical approaches to alleviate AD symptoms, effective 
options for long-term treatment of AD and methods to prevent its onset have yet to be 
discovered, for the complete mechanism of AD is unclear.  AD medications currently 
available help temporarily compensate for dysregulation of neurochemicals involved 
in the disease, but there is currently no modality that reverses or completely halts 
disease progression (Alzheimer’s Association, 2015).  Though the exact cause of AD 
remains unknown, extensive research is being conducted to understand the 
mechanisms of AD and to search for novel treatments.  
 
1.2  Characterization of Alzheimer’s Disease 
The Diagnostic and Statistical Manual of Mental Disorders-5 characterizes 
major NCD, formerly referred to as “dementia,” by a decline of performance in 




everyday activities and cannot be explained by another mental disorder (American 
Psychiatric Association, 2013).  Some major NCDs are considered reversible, 
meaning symptoms associated with these pathologies can be alleviated after 
treatment, but AD is currently irreversible and progressively worsens with time 
(Tripathi & Vibha, 2009). 
Cognitive symptoms of AD are characterized by the “4 A’s” of Alzheimer’s: 
amnesia, aphasia, apraxia, and agnosia (Alzheimer’s Foundation of America, 2016).  
Amnesia is a loss of memory, and occurs as deterioration, first, of short term memory 
and then of long term memory as the disease progresses.  The first “A,” amnesia, is a 
large contributing factor to the development of the other three “A’s.”  Aphasia is the 
inability to communicate effectively, which manifests in individuals suffering from 
AD as difficulty thinking of the appropriate words for communication.  Apraxia is the 
inability to perform pre-programmed motor tasks, and in AD, is caused by memory 
loss of motor skills learned during development.  Agnosia is the inability to properly 
interpret sensory signals.  In the context of AD, this emerges in different ways as the 
disease progresses, from no longer recognizing a person’s face to no longer 
understanding the meaning of the sensation of a full bladder.  These symptoms result 
in the inability to complete daily activities without significant assistance.  In addition 
to these cognitive symptoms, AD can also develop with major psychiatric symptoms, 
including personality changes, depression, hallucinations, and delusions.  Underlying 
these cognitive and psychiatric symptoms are the pathological hallmarks of AD in the 




meet the metabolic demands of healthy brain functioning (De La Monte & Wands, 
2008). 
 
1.3  Effects on Society 
AD not only affects its patients, but also takes a substantial toll on the families 
of patients.  In 2014, more than 15 million family members and other unpaid 
caregivers provided an estimated 17.9 billion hours of care to people with AD and 
varying NCDs, a contribution valued at more than $217.7 billion (Alzheimer’s 
Association, 2015).  
AD carries heavy financial, physical, and mental burdens for caregivers and 
family members.  As of 2015, the collective care costs for AD individuals in the 
United States totaled $226 billion, and approximately 18% of that cost had to be 
covered as out-of-pocket, not reimbursed by insurance, expenses for the families of 
AD patients (Figure 1).  By 2050, these costs are expected to grow to six times that 
amount, or to approximately $1.1 trillion (Alzheimer’s Association, 2015).  If the 
distribution remains unchanged, families will need to cover $330 billion of care costs.  
In addition, a 2015 survey reflected the significant physical and mental burdens on 
caretakers: 60% of caregivers reported high to very high stress levels, and 40% 
reported having depression (Alzheimer’s Association, 2015).  It is clear that AD’s 





Figure 1. 2015 Distribution of AD Expenditure. Costs of AD in America totaled 
$226 billion in 2015. Approximately $158 billion of the cost associated with AD care 
is covered by Medicare and Medicaid, while the remaining coverage falls to 
caregivers and totals a 68 billion dollar financial burden.  Information from 2015 
Alzheimer’s Disease Facts and Figures (2015).  Created by I. Green. 
 
1.3  Risk Factors and Diagnosis Of Alzheimer’s Disease 
1.3.1  Risk Factors   
Ninety-six percent of Americans with AD are 65 years of age or older, 
highlighting the importance of age as a risk factor for AD (Alzheimer’s Association, 
2015).  The risk of developing AD doubles every five years after the age of 65.  In 
addition to age, lifestyle and genetics are also risk factors (National Institutes of 
Health, 2016).  Smoking, obesity, lack of mental activity, and head trauma increase 
the likelihood of developing AD (National Institutes of Health, 2016).  Type 2 




disease by 50-60% (Chami et al., 2016; Mittal & Katare, 2016).  The comorbidity of 
AD and T2D appears to be more than just coincidence.   
Studies have been conducted since the 1990s to assess the relationship 
between AD and T2D.  In the majority of conducted studies, researchers found that 
increased body mass index and insulin resistance, both risk factors/indicators of T2D, 
were associated with increased risk of AD (Hammaker, 2014).  Compared to the 
general population, patients with T2D have a 50-150% increased risk for AD (Li, 
Song, & Leng, 2015).  Repeated evidence of this relationship fueled a group of 
researchers at Brown University to begin referring to AD as “Type III Diabetes” 
(Hammaker, 2014).  Both of these diseases involve glucose uptake deficits (De La 
Monte & Wands, 2008).  Even though AD involves aberrations in glucose 
metabolism in the brain, while T2D functions in the periphery, researchers 
hypothesize an interplay between these diseases (Moroz, Tong, Longato, Xu, & De 
La Monte, 2008; Sebastiao, Candeias, Santos, Oliveira, Moreira & Duarte, 2014).  
This research project focuses on the theory that AD is at least partially caused by 
improper glucose uptake.  
1.3.2 Types of Alzheimer’s Disease  
The genetic risk factors of AD vary in strength depending on the subtype of 
AD.  AD is characterized by two subtypes: familial and sporadic.  Familial AD is 
heavily dependent on genetics, as it is an autosomal dominant disease that is inherited 
through at least one of three known major genetic loci  (Rossor, Fox, Freeborough & 




AD, although certain genetic phenotypes may increase one’s susceptibility for the 
disease (Trippi, 2001). 
 Familial AD is the hereditary subtype of AD and as a result, more is known 
about its pathological development.  Genetic mutations that cause familial AD occur 
on the APP gene on Chromosome 21, the Presenilin 1 gene on Chromosome 14, or 
the Presenilin 2 gene on Chromosome 1 (Ryan & Rossor, 2010).  These three genes 
account for nearly all familial AD cases.  Additional research is being conducted to 
determine all of the genetic sites associated with familial AD pathology (Cruts, 
Theuns & Van Broeckhoven, 2012).  Although familial AD accounts for a minority 
of AD cases, it provides a useful way to study AD.   
While it is easier to study familial AD than sporadic, sporadic AD accounts 
for over 99.5% of all AD cases (Cruts et al., 2012).  This AD subtype is characterized 
by later onset and is not strongly associated with certain genotypes (Trippi, 2001).  
While not causative, genetics does play a role in regard to risk.  Carriers of the 
Apolipoprotein E (ApoE-ε4) allele are more likely to develop AD than those with a 
different version of ApoE-ε4.  Individuals with the ApoE-ε4 isoform represent 
roughly 20% of the population but make up 35-50% of sporadic AD cases 
(Hamerman, 2007; Alzheimer’s Association, 2015).  
1.3.3  Diagnosis  
Dr. Alzheimer characterized the plaques and tangles that define AD, 
specifically referred to as amyloid-beta (Aβ) plaques and neurofibrillary tangles 
(NFTs) made of tau paired helical filaments (PHF-tau), using staining methods 




are necessary for an official diagnosis of AD and can only be definitively determined 
post-mortem.  While post-mortem analysis is necessary for an official diagnosis, 
methods used to obtain information about AD biomarkers during life, such as 
analyzing cerebrospinal fluid, or brain scans such as positron emission tomography 
(PET), magnetic resonance imaging (MRI), and computerized tomography (CT), can 
help understand the progression of the disease up until death (Cipriani, Dolciotti, 
Picchi & Bonuccelli, 2010).  
Characterizing AD in a living patient is important for both medical 
management as well as research, and as a result, three stages of “probable AD” 
diagnosis are incorporated in the DSM-5.  These three stages, in order of increasing 
severity, are preclinical, mild NCD, and major NCD due to AD (Alzheimer’s 
Association & NIA, 2011).   The purpose of the diagnosis of preclinical AD is to 
measure early biomarker changes, in the absence of cognitive or behavioral 
symptoms, in someone who is predicted to have AD based on a family history or 
abundance of risk factors.  A diagnosis of mild NCD due to AD is a characterization 
of mild decline in cognitive and behavioral function that is not severe enough to 
affect independent functioning in everyday life.  With this diagnosis, evidence of 
biomarkers is highly encouraged to avoid an inaccurate diagnosis.  Finally, a 
diagnosis of major NCD due to AD is considered a complete manifestation of AD, 
involving severe behavioral and cognitive impairments that compromise a person’s 
ability to function independently in everyday life.  Although the psychiatric 
symptoms are sufficient for diagnosis, biomarker evidence helps increase diagnostic 




1.4 Experimental Approach 
As previously discussed, a recent focus of AD research has been the 
connection between AD and T2D.  Both diseases involve deficits in glucose transport 
from the blood into cells for metabolism, which is mediated by insulin.  For this 
reason, researchers are making connections between T2D and AD with existing 
knowledge about T2D treatment and intracellular processes.  To investigate the 
insulin signaling pathway (ISP) in AD, researchers use various drugs normally used 
for treatment of T2D.  One such class of drugs is the Thiazolidinediones (TZDs), 
which agonize downstream targets of the ISP to explore the compromised metabolic 
component of AD pathology (Leibiger, Leibiger & Berrggren, 2008; Zolezzi & 
Inestrosa, 2013).  While both insulin and TZDs have been used to investigate AD, the 
combined effects of the two have not been studied.  Doing so may provide useful 
since insulin facilitates cellular glucose uptake and TZDs agonize targets within the 
ISP to enhance insulin’s effects (Leibiger, Leibiger & Berrggren, 2008; Zolezzi & 
Inestrosa, 2013).  
Since the body’s blood brain barrier (BBB) only allows approximately 18% of 
pioglitazone (PGZ), a type of TZD, to cross from the periphery into the central 
nervous system (CNS) when administered orally, it is advantageous to deliver the 
drug directly to the brain where AD pathology occurs (Maeshiba et al., 1997).  In 
order to achieve this goal, drugs can be delivered using an intranasal delivery method 
(Talegaonkar & Mishra, 2004).   
Intranasal delivery of insulin to the brain has been performed in the context of 




trial, the Study of Nasal Insulin to Fight Forgetfulness (SNIFF), for intranasal insulin 
therapy is currently underway to test the effects of insulin nasal spray in adults with 
mild cognitive impairment or AD (University of Southern California, 2016).  
However, TZDs have never been administered in this or any other way to selectively 
target the CNS.  This study successfully executed the first intranasal administration of 
PGZ in conjunction with insulin to research AD pathology.  
 
1.5 Research Questions and Hypothesis 
This research aimed to determine the downstream metabolic components of 
the ISP that are aberrant in AD by modulating the activity of this pathway with 
intranasal insulin and PGZ during the onset of AD development.  Pathological 
markers of AD and glucose metabolism in the brain were measured to investigate 
aberrations in the ISP in the context of AD.  A transgenic mouse model expressing 
AD pathology was used to answer the following questions:  
1. Does intranasal administration of PGZ and insulin sensitize insulin 
signaling to increase glucose metabolism?  
2. Will three weeks of PGZ and insulin treatment reduce AD pathology? 
3. Do reductions in pathology persist two weeks after completing the 
dosing regimen?  
The combined treatment of insulin and PGZ was hypothesized to create long 





Chapter 2: Literature Review 
2.1  Pathology of Alzheimer’s Disease 
The AD brain is characterized by a prolonged immune response and increased 
apoptosis (Mandrekar & Landreth, 2010).  In addition, Aβ peptides and PHF-tau 
protein aggregates that form Aβ plaques and NFTs precede the cognitive and 
behavioral symptoms of AD (Wang et al., 2015).   This protein aggregation occurs in 
various parts of the brain, but the majority of severe pathology is concentrated in the 
hippocampus, the region in the brain predominantly responsible for learning and 
memory.  Certain subregions of the hippocampus are also associated with increased 
AD pathology (Willette, Modanlo & Kapogiannis, 2015).  Plaques first appear in the 
subiculum and then spread to the rest of the brain (George et al., 2014).  As the 
disease progresses, pathology spreads primarily to areas in the limbic system, such as 
the hippocampus and amygdala, which contributes to memory loss, disorientation, 
and behavioral changes (U.S. Department of Health and Human Services, n.d.). 
2.1.1  Amyloid Beta Plaques 
The starting point of AD progression is unknown, but several competing 
theories aim to explain the progression of the disease.  The amyloid cascade 
hypothesis, which is of particular relevance to this study, cites the imbalance between 
production and clearance of both internal and external Aβ plaques as the primary 
cause of AD (Zou et al., 2015).  This hypothesis suggests that the formation of Aβ 
plaques is the primary event in AD pathogenesis and is caused by the aggregation of 




natural cellular proteins. This pathogenic form causes the aggregation of peptides and 
yields a cascade of negative effects contributing to AD (Tong, Lou & Wang, 2015; 
Hardy & Selkoe, 2002).   These peptides are byproducts of altered amyloid precursor 
protein (APP) proteolysis.  APP is an integral membrane protein concentrated around 
the synapses of neurons that, when functioning properly, serves as a regulator of 
synapse formation, neural plasticity, and iron export (Turner, O’Connor, Tate & 
Abraham, 2003).  APP is normally broken down by α- and γ-secretases to produce 
sAPPα, which has neurotrophic and neuroprotective effects (Zhang, Ma, Zhang & 
Xu, 2012).  However, in AD, there is an altered pathway in which APP is cleaved by 
β-secretase, resulting in Aβ protein formation.  The tertiary structure of Aβ proteins 
can form dangerous oligomers that induce other Aβ proteins to aggregate, ultimately 
forming large Aβ plaques.  These resulting Aβ plaques are not only toxic to neurons, 
but also yield indirect effects on AD pathology.  These effects include triggering 
cascades of neuroinflammation, oxidative stress, tau hyperphosphorylation, and 
tangle formation, ultimately resulting in major NCD (Collins-Praino et al., 2014).  
2.1.2  Neurofibrillary Tangles 
In addition to the improperly cleaved proteins that contribute to Aβ plaques, 
another major contributor to AD pathology is the hyperphosphorylation of the 
structural protein tau.  Tau, a soluble protein found in neurons of the CNS, binds to 
and stabilizes microtubules, aiding the transport of nutrients, neurotransmitters, and 
cellular materials down the axon of a cell.  Tau can also act as a protein scaffold and 
participate in signal transduction cascades (Peric & Annaert, 2015).  Normally, tau is 




hyperphosphorylated version of tau is referred to as PHF-tau and causes the protein to 
become insoluble.  Insoluble tau self-aggregates and yields NFTs, which 
compromises tau’s cytosolic functions, dysregulating intracellular homeostatic 
mechanisms and leading to neuronal death (Mudher & Lovestone, 2002).  
Furthermore, Aβ-mediated neurotoxicity has been shown to require 
tau.  Cognitive decline associated with Aβ aggregation occurs only when 
accompanied by elevated levels of PHF-tau, which suggests that Aβ is an upstream 
modulator of tau hyperphosphorylation (Peric & Annaert, 2015).  
2.1.3  Inflammation  
Inflammation is an immune response in which affected tissue responds to 
harmful stimuli.  Inflammatory mediators help increase blood flow and accumulate 
defense cells in affected areas (Institute for Quality and Efficiency in Health Care, 
2015).  Microglia are brain immune cells that act similarly to macrophages in 
recognizing Aβ plaques as a signal of brain tissue damage (Mandrekar & Landreth, 
2010).  Once microglia are activated, they produce chemokines, a type of pro-
inflammatory signaling protein, to signal for more microglia activity to respond to the 
toxic Aβ plaque signal (Yoon & Kim, 2015).  
Although microglia are necessary in maintaining homeostasis under normal 
physiological conditions, long-term microglial activation can have detrimental effects 
on neurons.  In the presence of a manageable amount of Aβ plaques, microglia can 
successfully clear these plaques through phagocytosis and without a large 
inflammatory response (Mandrekar & Landreth, 2010).  However, once plaque 




microglia plateau.  Although the Aβ plaques can be internalized, digestion of these 
dense plaques is difficult within the phagocytic microglia (Yoon & Kim, 2015; 
Mandrekar & Landreth, 2010).  Thus, not all phagocytic activity completes Aβ plaque 
digestion, which can lead to a cascade of microglial aggregates surrounding tissue 
regions with high plaque content.  This initiates a positive inflammatory feedback 
loop because microglia recruited to digest the plaques fail and begin to send distress 
signals, attracting even more microglia.  Microglia release chemokines to create a 
pro-inflammatory environment in the brain. This reduces the phagocytic capabilities 
of microglial cells and causes further Aβ aggregation (Mandrekar & Landreth, 2010). 
2.1.4  Apoptosis  
Another major hallmark of AD is brain atrophy due to elevated levels of 
apoptosis triggered by the pathological Aβ plaques and NFTs (Xu et al., 
2012).  While this programmed cell death process is important for removing damaged 
or unnecessary cells, elevated levels deplete healthy brain cells that are important for 
proper functioning.  Apoptosis has two operating pathways, both of which are 
relevant to AD: extrinsic, which is activated by cell-surface death receptors, and 
intrinsic, which involves signals from mitochondria (Xu et al., 2012).   
In an extrinsic pathway (Figure 2), a signaling molecule called a Fas ligand 
attaches to a Fas death receptor on the surface of the cell, triggering the formation of 
a death-inducing signaling complex (DISC) in response to external apoptotic signals, 
such as Aβ plaques.  Effector caspases induce apoptosis through a caspase cascade 
triggered by initiator caspases within the DISC. Initiator caspases, such as caspase 8, 




7.  Executioner caspases such as these activate target proteins that break down the cell 
from the inside (Figure 2; Andersen, Becker & Straten, 2005).   
The intrinsic apoptosis pathway is mediated by mitochondria and initiated by 
the presence of cytoplasmic cytochrome c, which is suggestive of mitochondrial 
dysfunction and oxidative stress. Mitochondria regulate both energy metabolism and 
cell death pathways, fulfilling the high-energy requirements of the brain and 
stimulating apoptosis when necessary.  Therefore, mitochondria are appropriate 
indicators of neuron survival (Moreira et al., 2012). This link between apoptosis and 
mitochondrial dysfunction corresponds with the increased risk that age contributes to 
AD. Oxidative stress also causes mitochondria to become larger and more 
disorganized, especially with age.  This oxidative stress and mitochondrial 
dysfunction relates to AD beyond the apoptosis that occurs in the disease.  It also 
relates to AD through aberrations in glucose metabolism that yield oxidative stress 
because cells are not getting necessary amounts of glucose.  The presence of 
cytoplasmic cytochrome c is analogous to the caspase 8 signal in the extrinsic 
apoptosis pathway. Cytochrome c triggers formation of an apoptosome, which is 






Figure 2. Apoptosis Signaling Pathway. In the extrinsic pathway on the left, a Fas 
ligand attaches to a Fas death receptor and triggers formation of a DISC. The 
initiator caspase 8 activates effector caspases 3, 6, and 7 through a cascade, which 
causes cell death. In this intrinsic pathway, mitochondria and cytochrome c can 
trigger apoptosis through formation of an apoptosome that activates caspases 3, 6, 
and 7. This causes cell death.  Information from Alberts et al., (2008). Created by A. 
Zachery.  
 
Studies on apoptotic processes in AD have highlighted an important link 
between the intrinsic apoptotic pathway and improper APP proteolysis.  As 
previously discussed, APP is normally broken down by α- and γ-secretases to produce 




against apoptosis (Zhang, Ma, Zhang & Xu, 2012).  In AD, apoptosis is triggered by 
alternative cleavage of APP by β-secretase rather than α- and γ-secretases. This 
activates caspases 3 and 7 to trigger cell death (Fiorelli, Kirouac & Padmanabhan, 
2013).  In addition to starting this self-destruct mechanism, the improper cleavage of 
APP results in aggregated Aβ proteins, which inhibits production of protective sAPPα 
(Figure 3).  A decreased amount of sAPPα may contribute to brain degeneration in 
AD subjects (Zhang, Ma, Zhang & Xu, 2012).  For these reasons, caspase inhibitors 
are being studied as a potential therapy for AD. 
 
 
Figure 3.  APP Processing.  β-secretase cleavage of the N-terminal fragment of APP 
followed by action of γ-secretase in the membrane releases Aβ and leads to 






2.1.5  Diminished Cerebral Glucose Metabolism  
Diminished cerebral glucose metabolism (DCGM), or glucose 
hypometabolism, characterizes the abnormality in glucose metabolism occurring in 
AD (Small et al., 2000).  Studies ubiquitously show that severity of AD is highly 
correlated with glucose hypometabolism (Mosconi, Pupi & De Leon, 2008).  This 
problem with glucose metabolism is a reason that AD is referred to as “Type III 
Diabetes” (Sebastiao et al., 2014).  Glucose metabolism levels can be measured using 
PET scanning, which tracks disease progression (Levy, Zieve, & Ogilvie, 2014).  
When glucose metabolic levels were tracked in subjects with the APOE-ε4 genetic 
risk factor for sporadic AD, DCGM was found before detectable AD symptoms could 
be observed (Small et al., 2000).  Another study expanded on this study and showed 
that the incidence of DCGM in these APOE-ε4 carries often occurs decades before 
other detectable AD symptoms, at a mean age of 30.7 years, long before any 
cognitive impairment (Reiman & Chen et al., 2004).  
It remains unclear if glucose hypometabolism is a cause of AD or a symptom 
of AD. In AD’s earliest stages, glucose hypometabolism begins in the hippocampus 
and later spreads throughout nearly all cortical areas (Santi et al., 2001).  One 
probable explanation of DCGM preceding AD onset is that deficient energy 
metabolism would change the oxidative environment of neurons. This contributes to 
the progression of AD, resulting in a positive feedback mechanism of mitochondrial 





2.2  Glucose Metabolism 
As discussed above, DCGM is an important aspect of AD pathology.  DCGM 
research is a promising field of AD research, especially given the newly found 
relationship between AD and T2D.  A comprehensive understanding of DCGM 
requires a discussion of glucose uptake and metabolism. 
The body’s main source of energy is adenosine triphosphate (ATP), which is 
generated primarily through the oxidative metabolism of glucose.  Peripheral glucose 
levels are modulated by the pancreas; when blood sugar is low, the pancreas secretes 
glucagon.  Glucagon then signals the liver to break down stored glycogen into 
glucose, and the glucose is released into the bloodstream to return blood sugar to 
homeostatic levels (Leibiger, Leibiger & Berrggren, 2008).  When blood sugar is high 
the pancreas secretes insulin, which transports glucose into cells and lowers blood 
sugar. This facilitation of glucose into peripheral cells is regulated by the ISP.  In this 
pathway, extracellular insulin initiates an intracellular cascade of proteins that 
eventually activates glucose transporter 4 (GLUT4) to allow glucose into the cell 
(Leibiger, Leibiger & Berrggren, 2008).   
In the body’s periphery, GLUT4 and insulin are the main regulators of 
glucose uptake (Huang & Czech, 2007).  The brain and CNS mainly depend on 
insulin-independent mechanisms for glucose uptake, but insulin and GLUT4 still 
regulate some aspects of glucose metabolism in the brain (Bingham et al., 2002).  The 
differences between glucose metabolism in the body and the brain necessitates an 





2.2.1  Glucose Metabolism in the Brain  
Glucose is the fundamental source of energy in the brain, and the brain 
exhausts approximately 60% of the body’s available glucose in its resting state (Berg, 
Tymoczko & Stryer, 2002; Mobbs, Kow & Yang, 2001).  The brain consumes 120 
grams of glucose per day, primarily to maintain ion concentration gradients. These 
gradients are responsible for both the transmission of electrical information and 
neurotransmitter synthesis (Berg et al., 2002).  Due to the brain’s high metabolic 
demand, glucose must be facilitated across the BBB at a consistently high rate, 
regardless of fluctuations of blood glucose concentration or insulin levels.  For this 
reason, insulin-dependent GLUT4 is not the main glucose transport mechanism in the 
brain. Instead, insulin-independent glucose transporter 1 (GLUT1) and glucose 
transporter 3 (GLUT3) transporters are the major mechanisms by which glucose 
enters the CNS (El Messari et al., 2002).   
Glucose must be transported from the bloodstream through both the BBB and 
neuronal membranes in order to be metabolized in neurons (Figure 4). GLUT1 is 
mainly responsible for the constitutive transport of glucose through the BBB and 
GLUT3 is mainly responsible for the transport into neurons (Klepper & Voit, 2002; 
Simpson et al., 2008).  GLUT3 has a strong affinity for binding glucose, so even low 
glucose levels do not deter the rate of glucose uptake (Schulingkamp, Pagano, Hung 
& Raffa, 2000).  This feature of GLUT3 helps to satiate the brain’s high metabolic 
demand. 
Since the majority of glucose metabolism in the brain is insulin independent, 




occurred only recently.  The presence of GLUT4 and insulin receptors in the brain 
has now been experimentally proven (Shah, DeSilva & Abbruscato, 2012).   
Similarly to glucose, insulin is not produced in the brain and cannot passively 
diffuse through the BBB; it requires controlled receptor-mediated transport (Sartorius 
et al., 2015).  These transporters are expressed at various locations in the BBB but are 
most abundant in the olfactory bulb (Banks, Owen & Erickson, 2012).  Additionally, 
insulin receptors (IRs) are expressed throughout the cortex and hippocampus, 
allowing for insulin entry into neurons (Woods, Seeley, Baskin & Schwartz, 
2003).  IRs are generally more prevalent in areas with high GLUT4 concentrations, 
especially in motor areas and the hippocampus (Choeiri, Staines & Messier, 2002; El 
Messari et al., 2002).  Although the metabolic demand of the brain restricts insulin 
from completely controlling glucose uptake, insulin does act as a modulator to alter 
glucose uptake in some brain regions (Willette et al., 2015).  The hippocampus and 
subiculum in particular express high levels of GLUT4 messenger ribonucleic acid 
(mRNA).  The hippocampus is also associated with learning, memory, and AD 
pathology.  Additionally, Aβ plaque formation begins in the subiculum, which is why 
the presence of GLUT4 in the hippocampus and subiculum is important to the present 
study (George et al., 2014).   Understanding and researching the different aspects of 
glucose metabolism is imperative to the study of AD, as AD relates to DCGM 





Figure 4. Glucose Transport in the CNS. Glucose is transported from the 
bloodstream across the BBB to the brain extracellular space. In the BBB, the most 
abundant glucose transporter is GLUT1, although GLUT3 and GLUT4 are also 
expressed in lower quantities. From the brain extracellular space, glucose enters 
neurons through more glucose transporters. In the neurons, the most abundant 
glucose transporter is GLUT3, although GLUT1 and GLUT4 are also expressed. 
Information from: Shah, DeSilva, & Abbruscato, 2012. Created by S. Morken.  
 
2.3  Insulin Signaling Pathway 
The relationship between AD and T2D suggests that the insulin-dependent 
mechanisms of glucose uptake may contribute to AD and DCGM.  Therefore, this 
research focuses on how insulin signaling affects AD and requires a background on 





The Phosphoinositide 3-kinase (PI3K) pathway of insulin signaling is the cell 
transduction mechanism primarily responsible for translocation of GLUT4 to the 
plasma membrane (Yin et al., 2006; Chang, Chiang & Saltiel, 2004).  Extracellular 
insulin initiates an intracellular signal cascade that eventually translocates GLUT4 
(Yin et al., 2006).  In the PI3K pathway, insulin binds to the IR, which activates 
signaling protein Insulin Receptor Substrate 1 (IRS1) by tyrosine kinase 
phosphorylation (Yin et al., 2006).  IRS1 is the link between insulin receptor 
stimulation and the downstream ISP mechanisms that lead to transcription and 
reprogramming of cells (De Felice et al., 2014).  Activated IRS1 binds to the P85 
subunit of the PI3K molecule, which then activates Phosphoinositide dependent 
protein kinase-1 (PDK1), a master kinase that activates isoforms of protein kinase B 
(Akt1 and Akt2), and protein kinase C zeta (PKCζ) (Yin et al., 2006). 
Akt1 is a protein kinase that inhibits apoptosis and induces protein synthetic 
pathways to promote tissue growth (Kupriyanova & Kandror, 1999).  Akt2 not only 
prevents apoptosis but also ultimately leads to translocation of GLUT4 to the plasma 
membrane (Kupriyanova & Kandror, 1999).  PDK1 also phosphorylates and activates 
PKCζ, which associates with GLUT4 and aids in its translocation to the plasma 






Figure 5.  Simplified ISP.  Insulin binds to the insulin receptor and stimulates a 
cascade, ultimately resulting in the translocation of GLUT4 transporters. Information 
from: Braiman et al. 2001; Kupriyanova & Kandror, 1999; Yin et al., 2006. Created 
by S. Morken. 
 
This translocation can also be triggered by the activation of a Cbl/Cbl-
associated protein (CAP) complex.  Insulin can directly stimulate the activation of 
Cbl/CAP (Monsalve, Pyarasani, Delgado-Lopez & Moore-Carrasco, 2013).  When 
bound by insulin, Cbl, a receptor adapter protein, is recruited to the IR by CAP (Leto 
& Saltiel, 2012).  This performs a similar function to PI3K and facilitates the 




2.3.1  PPARγ 
A focus of this study is the role of the nuclear receptor (NR) Peroxisome 
Proliferator-Activated Receptor gamma (PPARγ).  Two relevant NRs, or transcription 
factors, within the ISP are retinoid X receptors (RXRs) and PPARs (Leonardini, 
Laviola, Perrini, Natalicchio & Giorgino, 2009).  PPARγ is a common isoform of 
PPAR that is involved in many bodily processes including lipid storage, energy 
metabolism, adipocyte differentiation, inflammation, and insulin sensitivity 
(Mandrekar-Colucci, Karlos & Landreth, 2012; Mandrekar-Colucci & Landreth, 
2011).  
PPARγ is a component of the downstream ISP that aids in increasing glucose 
uptake using two major strategies: transcription and translocation (Figure 6).  PPARγ 
facilitates the transcription of adiponectin, GLUT4, and Cbl/CAP (Figure 
7).  PPARγ’s insulin-dependent activation begins with the heterodimerization of 
PPARγ and RXR to create a transcription factor complex associated with a 
corepressor (Mandrekar-Colucci et al., 2012).  This dimer is bound to the PPAR 
response element (PPRE), which is located near the promoter of the target gene 
(Mandrekar-Colucci et al., 2012; Leonardini et al., 2009).  When no ligand is present, 
the promoter is in a repressed state that prevents transcription and represses the NRs, 
blocking gene expression.  Upon ligand binding, conformational change of the dimer 
induces corepressor release and coactivator association, releasing the complex from 
the PPRE and allowing for transcriptional proteins to bind to the PPRE.  This yields 
gene transcription of adiponectin, GLUT4, and Cbl/CAP (Mandrekar-Colucci et al., 




glucose to enter the cell and improve insulin sensitivity (Monsalve et al., 2013).  
Transcription of the Cbl/CAP complex enhances its translocating function of 
cytosolic and newly transcribed GLUT4 (Chiang et al., 2001).  It is for these reasons 
that PPARγ is considered an insulin sensitizer. 
 
Figure 6.  Simplified ISP Including PPARγ. PPARγ stimulates GLUT4 directly and 
through the Cbl/CAP complex.  Information from: Braiman et al., 2001; Kupriyanova 
& Kandror, 1999; Leonardini, Laviola, Perrini, Natalicchio & Giorgino, 2009; Leto & 
Saltiel, 2012; Monsalve, Pyarasani, Delgado-Lopez & Moore-Carrasco, 2013; Yin et 






Figure 7. The Insulin-dependent Mechanism of PPARγ Gene Transcription. (A) In 
the unstimulated state, PPARγ and RXR heterodimerize and associate with a 
corepressor. This complex is bound to the PPRE, blocking gene expression. When an 
agonist binds to PPARγ, conformational changes cause the corepressor to fall off the 




conformational change, which forces the complex off of the PPRE. (C) The absence 
of any complex on the PPRE allows transcriptional proteins like RNA polymerase to 
bind. RNA polymerase transcribes the gene to an mRNA that can get translated into 
proteins like adiponectin, Cbl/CAP, or GLUT4. Information from: Mandrekar-
Colucci et al., 2012; Leonardini et al., 2009; Monsalve et al., 2013; Chiang et al., 
2001. Created by S. Morken. 
 
Beyond its role in the ISP, PPARγ is also an anti-inflammatory compound.  In 
addition to its expression in metabolic tissue, PPARγ is expressed in a variety of 
immune cells (Széles, Töröcsik & Nagy, 2007).  Expression of PPARγ in immune 
cells inhibits inflammatory responses through its NR activity by decreasing 
macrophage activity (Széles et al., 2007).  
Understanding the activation of PPARγ is a key component to this study.  
PPARγ agonists are insulin sensitizers and allow more glucose to enter the cell.  This 
insulin-dependent mechanism of PPARγ and its effect on AD will be studied, as well 
as the anti-inflammatory aspects of PPARγ that affect other components of AD 
pathology. 
 
2.4  Current Alzheimer’s Disease Research: Thiazolidinediones 
and Insulin   
Current AD research focuses on treating the glucose hypometabolism using 
both insulin and PPARγ agonists.  One PPARγ agonist currently being studied in 




2.4.1  Thiazolidinediones and Alzheimer’s Disease  
PPARγ agonists such as TZDs help alleviate some symptoms and pathologies 
of AD.  PPARγ agonists have been found to improve learning in AD patients and 
reduce amyloid burden and plaque load in animal models (Liu, Wang, & Jia, 2015). 
Through PPARγ activation, TZDs both administered orally and directly-injected have 
been shown to reduce the different forms of AD pathology in multiple AD mouse 
models, including the triple-transgenic model (3x-Tg-AD) used in this study (Tamez-
Pérez, Quintanilla-Flores, Rodríguez-Gutiérrez, González-González & Tamez-Peña, 
2015).  Two common types of TZDs are Rosiglitazone (RGZ) and PGZ (Gupta & 
Gupta, 2012). 
Through PPARγ activation, TZDs have been shown to delay AD development 
using a variety of mechanisms affecting multiple AD pathologies (Zolezzi & 
Inestrosa, 2013).  TZDs have been shown to reestablish insulin sensitivity, reduce 
inflammation, clear Aβ plaques, increase mitochondria function, and prevent tau 
hyperphosphorylation (Winkelmayer, Setoguchi, Levin & Solomon, 2008; Lee, Hsu, 
Liao & Pan, 2011; Mandrekar-Colucci & Landreth, 2011; Tamez-Pérez et al., 2015).  
PPARγ increases the number of GLUT4 transporters in neuronal membranes, 
allowing increased glucose uptake and facilitating proper cellular function.  TZD 
activates PPARγ and Akt2 to stimulate glucose uptake into cells.  This also indirectly 
stimulates GLUT4 translocation by activating the Cbl/CAP complex (Leonardini, 
Laviola, Perrini, Natalicchio & Giorgino, 2009).  In addition, TZD protects against 




Pan, 2011).  Therefore, TZDs increase glucose uptake through upregulation of 
GLUT4 (Figure 8). This combats the AD brain’s decreased sensitivity to insulin.   
 
 
Figure 8.  Simplified ISP Including PPARγ and PGZ. PGZ stimulates both PPARγ 
and AKt2 to increase glucose uptake in cells through GLUT4 
translocation.  Information from: Braiman et al., 2001; Kupriyanova & Kandror, 
1999; Leonardini, Laviola, Perrini, Natalicchio & Giorgino, 2009; Leto & Saltiel, 
2012; Monsalve, Pyarasani, Delgado-Lopez & Moore-Carrasco, 2013; Yin et al., 





Additionally, PPARγ agonists reduce inflammation by polarizing microglia to 
the anti-inflammatory (M2) state.  This occurs through gene transactivation and gene 
suppression  (Mandrekar-Colucci & Landreth, 2011).  When the inflammatory 
response of macrophages is triggered by Aβ plaques, the increased levels of microglia 
and macrophages become neurotoxic and damage the brain.  Macrophages produce 
interleukin-6 (IL-6), which activates more macrophages, inflammatory agents, and 
tumor necrosis factor alpha (TNFα), which induces apoptosis (Rubio-Perez & 
Morillas-Ruiz, 2012; Tamez-Pérez et al., 2015).  PPARγ activated by TZD acts as 
anti-inflammatory agent by stopping the transcription of the nuclear factor Activator 
Protein 1 (AP-1).  This prevents microglia from becoming activated by Aβ plaques.   
Another function of TZD is the clearance of Aβ plaques.  The high AD risk 
allele, ApoE-ε4, is associated with reduced Aβ plaque clearance (Perez & Quintanilla, 
2015).  TZDs overexpress ApoE and increase Aβ clearance (Tamez-Pérez et al., 
2015).  There is also research showing that treatment with TZDs reduces the 
expression of the beta-secretase 1 (BACE1) enzyme that improperly cleaves APP in 
AD (Liu, Wang, Yan, Zhang, Pang & Liao, 2013).   
TZDs also prevent tau hyperphosphorylation in the hippocampi of both T2D 
and 3x-Tg-AD mouse models.  In AD, cyclin-dependent kinase 5 (Cdk5), which 
phosphorylates APP and tau, is overactive and phosphorylates both of these proteins 
at a faster rate than dephosphorylation.  This results in Aβ plaques and NFT protein 
aggregates (Liu et al., 2015). PPARγ decreases the levels of p35, a Cdk5 activator, 




c-Jun N-terminal kinase (JNK) signaling pathways in which Cdk5 is involved 
(Tamez-Pérez et al., 2015).  
Finally, TZDs increase mitochondria function.  Mitochondria in neurons are 
damaged from oxidative stress in AD.  A study of Aβ-injected Wistar rats, a model 
used to study aging, found that long-term TZD treatment reduced oxidative damage 
and produced more mitochondria.  Long-term potentiation (LTP), an important part 
of synaptic plasticity, was also increased with TZD treatment (Tamez-Pérez et al., 
2015; Prakash & Kumar, 2014). 
2.4.2  Insulin and Alzheimer’s Disease  
Some research suggests that the hyperinsulinemia associated with T2D is a 
risk factor for developing AD because it leads to decreased insulin signaling in the 
brain.  Decreased insulin signaling reduces the inhibition of a major tau kinase, 
thereby preventing phosphorylation of tau (Chami et al., 2016). 
Two important proteins in AD are JNK and TNFα. Increased JNK and TNFα 
activity has been recorded in transgenic AD mice models, monkeys injected with Aβ 
oligomers, and post-mortem brains from AD patients (De Felice et al., 2014).  In 
T2D, TNFα stimulation induces apoptosis and inhibits IRS1 by phosphorylation 
(Tamez-Pérez et al., 2015; De Felice, Lourenco & Ferreira, 2014).  This 
phosphorylation causes cells to become insulin resistant by blocking the downstream 
mechanisms of the ISP and causing the insulin receptors on the cell membrane to 
internalize (De Felice et al., 2014).  TNFα also triggers a JNK stress pathway that 




Aβ peptides decrease insulin’s affinity for its receptor. They are also 
competitive insulin inhibitors through the function of insulin degrading enzyme 
(IDE), which acts on both insulin and Aβ peptides (Farris et al., 2003).  The ApoE-ε4 
gene has been associated with decreased levels of IDE (Wang, Dickson & Malter, 
2006).  This gene also reduces IDE levels by activating N-methyl-D-aspartate 
(NMDA) receptors in hippocampal neurons.  IDE will degrade Aβ proteins in the 
absence of high levels of insulin.  However, if insulin is able to bind to the IRs, 
insulin levels will increase, which in turn will cause an increase in IDE that can 
degrade more Aβ plaques (Du, Chang, Guo, Zhang & Wang, 2009). 
2.4.3  Intranasal Administration of Insulin and Thiazolidinediones  
Many current insulin studies administered treatment intranasally to focus 
doses in the CNS and cross the BBB. For a molecule to cross the BBB, three main 
criteria are considered: hydrophilicity versus lipophilicity, molecular weight, and 
degree of ionization.  Molecules that are lipophilic, nonionized, and have a molecular 
weight of less than 300 Daltons yield the quickest and most efficient absorption 
(Grassin-Delyle et al., 2012).  
During intranasal administration, treatments enter the nasal cavity and are 
then absorbed by the nasal mucosa through passive diffusion.  Molecules then enter 
the brain either through axonal transport or by bulk flow through the olfactory and 
perineural channels of the extraneuronal pathway (Talegaonkar & Mishra, 2004; 
Hanson, Fine, Svitak & Faltesek, 2013). 
One study investigated the effects of eight weeks of intranasal insulin 




(Benedict et al., 2004).  Results showed that subjects experienced improvement in 
recall of words and enhanced mood.  Blood glucose and plasma insulin remained 
constant between treatment and placebo groups, which indicated that the intranasal 
method did not cause peripheral side effects.   
Another study tested the effect of intranasal insulin administration on both 
cognition and Aβ peptides.  Intranasal insulin treatment was administered daily to 
patients with early AD for 21 days (Reger et al., 2007).  Like the previous study, 
plasma glucose and insulin levels were unchanged between the treatment and placebo 
groups.  The insulin-treated subjects retained more verbal information and showed 
improved attention when compared to the placebo-assigned subjects (Reger et al., 
2007).  
Although intranasal insulin has been studied extensively, TZDs have never 
been administered intranasally (Freiherr et al., 2013).  Intranasal administration of 
insulin for researching and treating AD provides a framework for this research 
method. Combining the method of intranasal administration with PGZ, an insulin 
sensitizer, allows examination of the role of the ISP and T2D drugs in AD 
development and pathology.  Additionally, the aforementioned studies have indicated 
that intranasal insulin administration does not have systemic effects (Benedict et al., 
2004).  Based on this, it can be predicted that intranasal PGZ administration would 





Chapter 3: Research Strategy 
The purpose of the study was to further elucidate the role of the downstream 
ISP in the development of AD pathology.  PGZ was chosen as the type of TZD 
investigated in this study as it has fewer side effects, especially negative 
cardiovascular effects, than RGZ does (Winkelmayer, Setoguchi, Levin & Solomon, 
2008).  PGZ and insulin were administered intranasally in order to address the 
following research questions:  
1. Does intranasal administration of PGZ and insulin sensitize IR 
signaling to increase glucose metabolism?  
2. Will three weeks of PGZ and insulin treatment reduce AD pathology?  
3. Do reductions in pathology persist two weeks after completing the 
dosing regimen?   
The combined treatment of insulin and PGZ was hypothesized to create longer 
lasting effects and reduced AD pathology in comparison to an insulin only treatment 
as a result of improved glucose uptake.  An initial pilot study was performed on non-
transgenic mice in order to validate and refine methods of intranasal administration of 
PGZ and insulin.  The main study was then performed on an AD mouse model, and 
was carried out in three phases to address the research questions.  
 
3.1  Intranasal Method 
The intranasal method was used to administer treatments in this study because 




peripheral effects in the blood (Talegaonkar & Mishra, 2004).  A safety study of 
intranasally administered insulin revealed no nasal irritation or differences in blood 
glucose concentrations (Kupila et al., 2003).  
As previously noted, PGZ does not easily cross the BBB through the 
bloodstream (Maeshiba et al., 1997). Therefore, an intranasal method of delivering 
PGZ was developed in this study in order to bypass the BBB and enter the brain 
through the olfactory pathway, mirroring intranasal insulin administration.  
 
3.2  Pilot Study 
In order to refine the intranasal delivery method, a pilot study was performed 
in order to determine if intranasal administration of PGZ was viable and to determine 
an optimal dose of intranasal PGZ, as there was no precedent from previous 
literature.  Glucose uptake was measured through fluxomics analysis in order to 
assess the effects of PGZ administration and its ability to pass the BBB.  
Additionally, the pilot study supported aims of the Institutional Animal Care and Use 
Committee (IACUC) to reduce the number of and risk to animals used for the Main 
Study.  Thus, both technique and feasibility were affirmed and refined with the Pilot 
Study.  
Previously, studies using PGZ only involved oral administration of the drug.  
The dosage of intranasal PGZ was determined by referring to the dose of oral PGZ 
given in previous studies for peripheral metabolism (Heneka et al., 2005).  Then, the 
weight and metabolism rate of the brain was used to calculate an intranasal 




Based on this calculation, three dosing amounts were tested – 15 µg, 30 µg, and 60 
µg.  Each PGZ concentration was combined with 120 µg of insulin dissolved in a 24 
µL dose (Renner et al., 2012).  A detailed record of the calculations can be found in 
Appendix D.  
Eight nontransgenic C57/BL6 mice, which demonstrated no AD pathology, 
were assigned to four experimental groups. Two mice received intranasal 
administration vehicle only (acidic saline) as a control.  Additional groups of mice 
received 15 µg of PGZ (n = 2), 30 µg of PGZ (n = 2), and 60 µg of PGZ (n = 2) each 
dissolved in 24 µL of acidic saline.  Treatments were administered, behavioral 
responses were noted, and mice were given an intraperitoneal injection of 13C-labeled 
glucose tracer.  Mice were necropsied for sample collection 24 hours after drug 
administration, and brains were extracted for fluxomics analysis.  Results obtained 
from the fluxomics analysis indicated all doses of PGZ increased brain glucose 
uptake when compared to the control, and the largest increase occurred with 60 µg 
PGZ.  Based on these results, 60 µg was selected as the optimal dose of PGZ for the 
Main Study. 
 
3.3  Experimental Design: Main Study 
3.3.1  Mouse Model   
The majority of AD research is conducted using transgenic rodent models 
expressing familial gene mutations.  Mouse models are appropriate for research on 
both familial and sporadic AD because both of these subtypes share similar clinical 




A 3x-Tg-AD mouse model was used in this study, which contained the 
PS1M146V, tauP301L, and APPSwe transgenes (Oddo et al., 2003).  The addition of 
human APP and tau transgenes causes the mouse model to exhibit both plaques and 
tangles, serving as an appropriate model to study AD (Chin, 2011).  In the 3x-Tg-AD 
model, there is no meaningful difference in pathology between male and female mice, 
so both sexes were used in the study (Oddo et al., 2003).  Expected pathological onset 
of this mouse strain, defined by when significant amounts of both Aβ plaques and tau 
tangles would be detectable, was anticipated to occur at 12-15 months of age 
(Blázquez, Cañete, Tobeña, Giménez-Llort & Fernández-Teruel, 2014).  
The 3x-Tg-AD mouse has been an effective model to study the effects of 
insulin on AD pathology.  Vandal et al. (2014) investigated the effects of a single 
insulin dose on the increased memory impairments caused by a high-fat diet in a 3x-
Tg-AD mouse model.  The insulin dose reduced the memory effects and Aβ levels 
and not only did the model effectively mimic desired AD pathology, but the 
experiment further supports the link between AD and T2D.  Another study by 
Sancheti et al. (2014) used a younger 3x-Tg-AD mouse model to investigate the 
therapeutic effects of lipoic acid, a compound that mimics insulin, on the 
hypermetabolism associated with AD.  Glucose metabolism was measured with a 
similar 13C labeling method to the proposed study, and the lipoic acid was found to 
reduce hypermetabolism in the model to levels of a control model. Searcy et al. 
(2012) used the 3x-Tg-AD mouse model to investigate the effects of oral pioglitazone 
on AD pathology and confirmed the results of prior animal studies that TZDs can 




The literature has demonstrated that this mouse model not only develops 
similar AD pathology to humans, but it also responds to treatment with insulin and 
TZD accordingly, making it a reasonable model to use for the proposed study.  
3.3.2  Subiculum  
The subiculum is a subregion of the hippocampus (Figure 9) where plaque 
formation begins (George et al., 2014).  Because many relevant AD pathological 
markers are present in this region, the subiculum was identified as the area of interest 
when analyzing immunohistochemistry (IHC) results.  In addition, unpublished 
pathological progress data suggests that the subiculum is an appropriate structure to 
use for analysis of IHC endpoints, specifically in the colony of 3x-Tg-AD mice used 
for this study (unpublished data, Ottinger Lab).  
 
Figure 9. Anatomical Features of a Mouse Brain. (A) Schematic Representation of 




Relationships.  Modified from Paxinos and Franklin (2001).  (B*) Congo red staining 
was utilized to visualize amyloid plaque formation in 14-month old 3x-TTG, arrows 
denote selected plaques.  LV = lateral ventricle, CA1= CA1 Hippocampus, DG = 
dentate gyrus, Ctx=Cortex, Mid = Midbrain, Cb=Cerebellum. * Representative 
image provided by Dr. Kara Duffy (unpublished, 2005).  
 
3.3.3  Treatment Groups  
Three treatment groups were used in the study:  24 µL of acidic saline, 120 µg 
insulin dissolved in 24 µL, and a combination of 120 µg insulin and 60 µg PGZ 
dissolved in 24 µL (PGZ+Insulin) (Renner et al., 2012). 
The Saline treatment group was used as a control.  PGZ+Insulin was 
administered because TZDs had been shown to upregulate insulin receptors (Searcy 
et al., 2012).  Combining insulin with PGZ would reduce the likelihood that insulin 
levels act as a limiting factor to the effects of PGZ.  Because the PGZ+Insulin 
treatment included insulin, an Insulin only treatment group was administered to 
determine if any changes in glucose metabolism and pathology were attributed to 
solely insulin or insulin sensitization by PGZ. 
3.3.4  Study Phases  
Forty-five mice were grouped into three cohorts of 15 mice based on age to 
control for degree of pathology.  Three treatment groups (Saline, Insulin, and 
PGZ+Insulin) were used within each phase (n=5) (Figure 10).  Phases varied both in 





Figure 10.   Phases in Main Study. A schematic of the phases used in this 
study.  Created by I. Green. 
 
The aim of Phase I was to validate that 3x-Tg-AD mice would be affected by 
the intranasal dosing method similarly to the non-transgenic mice in the Pilot Study. 
Mice were administered one intranasal treatment, and samples were collected 24 
hours after administration. 
The aim of Phase II was to observe the effects of a long-term intranasal 
treatment on AD pathology as well as brain glucose metabolism.  Mice were 
administered intranasal treatment daily for three weeks, and samples were collected 




The aim of Phase III was to observe the lasting effects of long-term intranasal 
treatment on AD pathology and brain glucose metabolism.  Mice were administered 
intranasal treatment daily for three weeks, and samples were collected two weeks 
after the last administration. 
3.3.5  Immunohistochemistry Antibodies 
In order to measure pathological hallmarks of AD, IHC tests were performed 
using antibodies specific to pathological targets, and then were visualized with light 
microscopy.  Aβ plaque load can be measured through IHC, using the 6E10 antibody 
to quantify amyloid deposition (Gupta et al., 2014).  AT-8 is a phosphorylation-
specific tau antibody used in IHC to test for the presence of PHF-tau (Koga, Kojima, 
Kuwabara & Yoshiyama, 2014).  As another hallmark of AD, microglial activation is 
often measured to quantify inflammation in the brain. This can be done through IHC 
tests using anti-Ionizing calcium-binding adaptor molecule 1 (Iba1) antibody, which 
measures activation of microglia (Koga et al., 2014; Gupta et al., 2014).  
3.3.6  Fluxomics 
Fluxomics analysis was used in the study to determine whether the rate of 
glucose metabolism was affected by the experimental treatments.  Fluxomics is the 
study and quantitative measurement of the rate of metabolic reactions in cells, tissues, 
or organs during cell processes (Griffin, 2006).  Fluxomics utilizes stable isotope 
labeling to measure the quantities of metabolites present at a specific moment during 
a metabolic process.  In fluxomics, an organism can be labeled with a stable isotope 




chromatography-mass spectrometry (GC-MS) can be used to analyze tissue to 
measure quantities of metabolites present during a metabolic process.  A pattern-
recognizing computer program identifies the metabolic phenotype of a genetic 
modification by separating the metabolic changes associated with the modification or 
cell process from the already existing metabolic variations of an organism, therefore 





Chapter 4: Methodology 
4.1  Animal Care   
All animal procedures were submitted to and approved by the IACUC in the 
spring of 2014, and mice were handled in accordance with the University of 
Maryland and Animal Care guidelines (Appendix B).  Mice were acclimated to their 
surroundings and to the team members performing the procedure for several weeks 
prior to study execution.  For more information about the living environment of the 
mice, see Appendix B.  
 
4.2  Intranasal Administration 
Treatments were administered intranasally by dripping treatment into each 
mouse’s nostrils with a Hamilton syringe.  Appendix C details the intranasal grip 
method used to immobilize the mice during administration.  This method was an 
alternative to frequent anesthetization, reducing stress and unwanted side effects.  
Treatment drops were administered to alternating nostrils, allowing enough time for 
each nostril to clear before proceeding to the next (Renner et al., 2012).  In order to 
administer PGZ intranasally, a diluted saline solution of PGZ was made manually by 
dissolving 60 µg, the optimal dose determined through the Pilot Study, into acidic 
saline. A detailed explanation of the intranasal administration method can be found in 




4.3  Sample Collection 
Stable isotope labeling was used to assess potential changes in glucose 
metabolism between treatment groups.  Two hours before sacrificing, 13C glucose 
tracer was injected intraperitoneally into mice.  Injecting and sacrificing procedures 
were staggered to ensure that the tracer remained in each mouse for no more or less 
than two hours.  13C glucose tracer was then detected via post-mortem fluxomics 
analysis of brain samples.  
In accordance with an approved IACUC protocol, animals were humanely 
euthanized and tissue samples were collected for analysis.  After decapitation, blood 
was collected and brains were removed within minutes of death (Spijker, 2011). 
Brains were then hemisected.  The left hemisphere was frozen and stored at -80°C for 
future metabolic analysis.  The right hemisphere was fixed in 10% formalin for 72 
hours and then moved to fresh 1x phosphate buffered saline (PBS).  Fixed tissue was 
paraffin embedded and sagittal sections were prepared (American Histolabs, 
Gaithersburg MD).  Slides were later processed using immunostaining methods 
(Shankar et al., 2009). 
 
4.4  Immunohistochemistry 
6E10 (Aβ deposition), Iba1 (microgliosis), and AT8 (PHF-tau) antibodies 
were used, and modified staining procedure was performed to identify 
immunoreactivity in the subiculum (Gupta et al., 2014; Koga et al., 2014).  Regions 




stereotaxic atlas (Paxinos, Watson, & Emson, 1980).  Primary antibodies included a 
mouse 6E10 antibody (1:300, Covance Inc., Princeton NJ), rabbit Iba1 antibody 
(1:150, Wako Chemicals USA, Richmond VA), and human AT8 antibody (1:100, 
Thermo Fisher Scientific, Waltham, MA). 
Slides were deparaffinized in xylene and hydrated in graded ethanol prior to 
antibody staining.  Following permeabilization and blocking, tissue sections were 
incubated with primary antibodies and followed with appropriate biotinylated 
secondary antibodies (Vector Labs, Burlingame CA).  Vectastain ABC kit (Vector 
Labs, Burlingame CA) was applied to slides and Vector DAB peroxidase substrate kit 
(Vector Labs, Burlingame CA) was utilized to view labeled protein in regions of 
interest.  Additional IHC controls were included to exclude nonspecific staining due 
to interference from secondary mouse antibodies from analysis.  Slides were then 
counterstained with hematoxylin to visualize nuclei.  Slides were mounted using 
Vectamount permanent mounting medium (Vector Labs, Burlingame CA) and left 
overnight to dry before imaging. 
 
4.5  Image Analysis  
After IHC staining to identify proteins of interest, brain slices were examined 
and imaged using a Zeiss AxioObserver.Z1 (Zeiss, Germany) microscope (2.5x 
Objective, 0.07 aperture) to assess AD pathology.  IHC endpoints were analyzed in 
the subiculum region of the hippocampus.  Images were captured using ZEN 2012 




Trained observers identified positive staining for each antibody.  6E10 
positive staining was counted for two micrographs from each animal.  Counts were 
averaged to determine differences between groups for each study phase.  Trained 
observers also examined slides and semi-quantified both AT8 and Iba1 staining using 
a Likert scale.  A three-point Likert scale was developed to include rankings of “low”, 
“medium”, and “high” levels of staining corresponding to scores of 1, 2, and 3 
respectively (Appendices E and F).  This three-category quantification scheme was 
used because the nature of the Iba1 and AT8 staining was not conducive to counting 
discrete units, so a more general means of quantification was necessary.  To combat 
the subjective nature of ranking with a Likert scale, images were ranked by 12 
individuals and averages were taken. 
 
4.6  Statistics 
After the IHC results were quantified, a two-way statistical test was used to 
determine whether changes between treatment groups were statistically 
significant.  The Kruskal-Wallis is a nonparametric test that analyzes the variance 
between three or more independently sampled groups and allows for different sample 
sizes (McKnight & Najab, 2010).  Due to the nature of data scored with the Likert 
scale, nonparametric statistical tests were needed to analyze the AT8 and Iba1 assays.  
A normal distribution for 6E10 assay data could not be assumed, thus a 
nonparametric test was required for this data as well.  If the differences were found to 
be significant, a Steel-Dwass test was then used to make pairwise comparisons 




Due to small sample sizes, and in order to decrease probability of Type I error, 
statistical significance was established at the α=0.1 level for all tests.  Means and 
standard errors were calculated and graphed for each treatment group. 
 
4.7  Luminescence Assay 
Caspase 3/7 and Caspase 9 assays were performed to measure apoptosis. 
Frozen brains were thawed on ice in T-Per buffer (Thermo Scientific, Waltham MA) 
containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis MO) for tissue 
homogenization. Homogenates were analyzed for Caspase 3/7 and Caspase 9 activity 
according to the manufacturer’s standard protocol (Promega, Madison, WI).  Briefly, 
a 25 µL sample was mixed gently for 30s with 25 µL Caspase-Glo 3/7 reagent in 
white-walled 96-well plates and incubated for 2h at room temperature in the dark.   
Lysis buffer with the caspase reagent served as a blank.  All samples were run in 
duplicate.  Luminescence was measured using a FLUOstar Omega microplate reader 
(BMG Labtech, Cary NC) and values were expressed as relative intensity units (RIU) 
to compare between groups for each phase of study. 
 
4.8  Fluxomics 
13C glucose tracer was injected intraperitoneally in mice before sacrificing. 
This tracer was used to indicate the rate of glucose metabolism in the brain.  Brain 
samples were homogenized, followed by the use of chloroform to remove lipids from 




under nitrogen to isolate glucose.  Following glucose extraction and separation, Di-O-
isopropylidene Acetate (IPAc) derivatives of hexoses were acetylated, ensuring that 
the samples could be analyzed using GC-MS (Hachey, Parsons, McKay & Haymond, 





Chapter 5: Results 
Results were obtained from three post-mortem IHC tests, luminescence 
assays, and fluxomics analysis.  
 
5.1  Immunohistochemistry 
5.1.1  6E10 (Aβ plaque) 
3x-Tg-AD mice were divided by intranasal treatment with groups of Saline, 
Insulin, or PGZ+Insulin.  6E10 immunoreactivity was counted in the subiculum to 
assess amyloid deposition in each phase of study.  In Phase I (Figure 11), samples 
were collected 24 hours after a single treatment.  Mean amyloid deposition count for 
Saline was 0.50±0.079, mean count for Insulin was 3.0±1.2, and mean count for 
PGZ+Insulin was 1.5±0.84.  Observed 6E10 immunoreactivity was similar across 





Figure 11. Amyloid Deposition Phase I.  (A) Representative images of 6E10 
immunostaining in the subiculum of 3x-Tg-AD mice from each treatment group.  (B) 
Pathology was quantified and histogram depicts mean ± standard error of the mean 
(SEM) amyloid deposition. Statistical analysis revealed no significant differences 
(p=0.222, χ2(2)=3.01). 
 
In Phase II (Figure 12), samples were collected 24 hours after three weeks of 
daily treatment.  Mean count for Saline was 21.2±7.2, mean count for Insulin was 
14.3±4.9, and mean count for PGZ+Insulin was 3.6±1.4.  A Kruskal-Wallis test was 
significant (p=0.038, χ2(2)=6.52) and a post hoc test using pairwise comparisons 
yielded significance for Saline vs. PGZ+Insulin (p=0.056), but not for Saline vs. 





Figure 12. Amyloid Deposition Phase II.  (A) Representative images of 6E10 
immunostaining in the subiculum of 3x-Tg-AD mice from each treatment group.  (B) 
Pathology was quantified and histogram depicts mean ± SEM amyloid 
deposition.  Statistical analysis revealed significant group differences (p=0.038, 
χ2(2)=6.52).  Post hoc tests revealed significant difference between Saline (a) and 
PGZ+Insulin (b) treatment groups (p=0.056). 
 
In Phase III (Figure 13), samples were collected two weeks after three weeks 
of daily treatment.  Mean count for Saline was 19.6±4.5, mean count for Insulin was 
4.8±3.2, and mean count for PGZ+Insulin was 5.1±2.2.  A Kruskal-Wallis test was 
significant (p=0.035, χ2(2)=6.71) and a post hoc test using pairwise comparisons 
yielded significance for Saline vs. PGZ+Insulin (p=0.056) but not for Saline vs. 





Figure 13. Amyloid Deposition Phase III.  (A) Representative images of 6E10 
immunostaining in the subiculum of 3x-Tg-AD mice from each treatment group.  (B) 
Pathology was quantified and histogram depicts mean ± SEM amyloid 
deposition.  Statistical analysis revealed significant group differences (p=0.035, 
χ2(2)=6.71).  Post hoc tests revealed significant difference between Saline (a) and 
PGZ+Insulin (b) treatment groups (p=0.056). 
 
5.1.2  Iba1 (Inflammation) 
Another IHC test performed was Iba1 for activated microglia.  Iba1 levels 
were quantified using a Likert scale in the subiculum to assess inflammation in each 
phase of the study.  In Phase I (Figure 14), samples were collected 24 hours after a 
single treatment.  Mean rating for Saline was 1.1±0.078, mean rating for Insulin was 




immunoreactivity was similar across groups and statistical analysis was not 
significant (p=0.361, χ2(2)=2.04). 
 
 
Figure 14. Iba1 Activated Microglia Ranking Phase I.  (A) Representative images of 
Iba1 immunostaining in the subiculum of 3x-Tg-AD mice from each treatment 
group.  (B) Pathology was quantified and histogram depicts mean ± SEM 
inflammation rating.  Statistical analysis revealed no significant differences 
(p=0.361, χ2(2)=2.04). 
 
In Phase II (Figure 15), samples were collected 24 hours after three weeks of 
daily treatment.  Mean rating for Saline was 2.5±0.21, mean rating for Insulin was 
1.4±0.14, and mean rating for PGZ+Insulin was 1.1±0.14.  A Kruskal-Wallis test was 




yielded significance for Saline vs. Insulin (p=0.056) and Saline vs. PGZ+Insulin 
(p=0.026) but not for PGZ+Insulin vs. Insulin (p=0.196). 
 
 
Figure 15. Iba1 Activated Microglia Ranking Phase II.  (A) Representative images 
of Iba1 immunostaining in the subiculum of 3x-Tg-AD mice from each treatment 
group.  (B) Pathology was quantified and histogram depicts mean ± SEM 
inflammation rating.  Statistical analysis revealed significant group differences 
(p=0.0054, χ2(2)=10.45).  Post hoc tests revealed significant difference between 
Saline (a) and Insulin (b) treatment groups (p=0.056) and Saline (a) and 
PGZ+Insulin (b) treatment groups (p=0.026). 
 
In Phase III (Figure 16), samples were collected two weeks after three weeks 
of daily treatment.  Mean rating for Saline was 2.8±0.071, mean rating for Insulin was 




significant (p=0.027, χ2(2)=7.23) and a post hoc test using pairwise comparisons 
yielded significance for Saline vs. Insulin (p=0.030) but not for Saline vs. 
PGZ+Insulin (p=0.258) or PGZ+Insulin vs. Insulin (p=0.731). 
 
 
Figure 16. Iba1 Activated Microglia Ranking Phase III.  (A) Representative images 
of Iba1 immunostaining in the subiculum of 3x-Tg-AD mice from each treatment 
group.  (B) Pathology was quantified and histogram depicts mean ± SEM 
inflammation rating.  Statistical analysis revealed significant group differences 
(p=0.027, χ2(2)=7.23).  Post hoc tests revealed significant difference between Saline 





5.1.3  AT8 (PHF-tau) 
Another IHC test performed was AT8 immunostaining.  AT8 levels were 
quantified using a Likert scale in the subiculum to assess PHF-tau prevalence in each 
phase of the study.  In Phase I (Figure 17), samples were collected 24 hours after a 
single treatment.  Mean rating for Saline was 1.4±0.065, mean rating for Insulin was 
1.8±0.36, and mean rating for PGZ+Insulin was 1.3±0.12.  Observed PHF-tau 
immunoreactivity was similar across groups and statistical analysis was not 
significant (p=0.435, χ2(2)=1.67). 
 
 
Figure 17. AT8 PHF-Tau Phase I.  (A) Representative images of AT8 
immunostaining in the subiculum of 3x-Tg-AD mice from each treatment group.  (B) 
Pathology was quantified and histogram depicts mean ± SEM PHF-Tau 





In Phase II (Figure 18), samples were collected 24 hours after three weeks of 
daily treatment.  Mean rating for Saline was 2.3±0.11, mean rating for Insulin was 
2.4±0.16, and mean rating for PGZ+Insulin was 2.3±0.11.  Observed PHF-tau 
immunoreactivity was similar across groups and statistical analysis was not 
significant (p=0.810, χ2(2)=0.422). 
 
 
Figure 18. AT8 PHF-Tau Phase II.  (A) Representative images of AT8 
immunostaining in the subiculum of 3x-Tg-AD mice from each treatment group.  (B) 
Pathology was quantified and histogram depicts mean ± SEM PHF-Tau 
rating.  Statistical analysis revealed no significant differences (p=0.810, 
χ2(2)=0.422). 
 
In Phase III (Figure 19), samples were collected two weeks after three weeks 




1.8±0.064, and mean rating for PGZ+Insulin was 2.1±0.093. Observed PHF-tau 
immunoreactivity was similar across groups and statistical analysis was not 
significant (p=0.110, χ2(2)=4.41). 
 
 
Figure 19. AT8 PHF-Tau Phase III.  (A) Representative images of AT8 
immunostaining in the subiculum of 3x-Tg-AD mice from each treatment group.  (B) 
Pathology was quantified and histogram depicts mean ± SEM PHF-Tau 
rating.  Statistical analysis revealed no significant differences (p=0.110, χ2(2)=4.41). 
 
5.2  Luminescence Assays 
In carrying out the luminescence assays, the majority of samples in each phase 
were below the detection limit of Caspase 3/7 and Caspase 9. Thus, resulting data was 




5.3  Fluxomics 
Phase II and Phase III fluxomics data was processed, however, it was lost due 
to GC-MS computer failure before it was able to be analyzed.  A different GC-MS 
machine was used to process the Phase I samples, and fluxomics data was obtained. 
As of publication time, the process of identifying the glucose in the fluxomics data 
has not yet been completed.  A standard is necessary to determine the expected 
fluxomics response of the labeled glucose, which will enable the location of potential 
glucose peaks in the fluxomics data for Phase I to be identified.  Once this is 
completed, the fluxomics data will be able to be analyzed to determine the effect of 
the intranasal treatments on glucose uptake.  Therefore, further statistical analysis has 






Chapter 6: Discussion 
The goal of this study was to investigate the effects of intranasal 
administration of PGZ+Insulin on a 3x-Tg-AD mouse model.  Three phases were 
conducted to test various lengths of treatment, as well as short and long-term waiting 
periods between treatment and sacrifice.  Fluxomics analysis of Phase I was expected 
to show elevated glucose uptake in the PGZ+Insulin treatment, followed by a slight 
increase in glucose uptake in the Insulin only group.  In the long-term treatment 
phases of the study, Phases II and III, the PGZ+Insulin treatment was expected to 
decrease AD pathology more than an Insulin treatment alone, and both of these 
treatment groups were expected to exhibit less pathology than the Saline 
treatment.  AD pathology was measured using IHC targeting Aβ deposits, PHF-tau, 
and activated microglia.  Glucose metabolism was measured using fluxomics analysis 
and caspase activity was measured using luminescence assays. 
In Phase I, a single dose of each treatment (Saline, Insulin, and PGZ+Insulin) 
was administered to mice that were then sacrificed 24 hours post-treatment.  This 
phase was designed to investigate the effects of intranasal administration of 
treatments on brain glucose metabolism in 3x-Tg-AD mice. 
As no detectable 13C sample was found through Phase I fluxomics results, it is 
hypothesized that the increased glucose observed in the Pilot Study after immediate 
sacrifice of one intranasal PGZ+Insulin administration also took place in the 3x-Tg-





Analysis of pathological endpoints showed low levels of AD pathology 
(amyloid depositions, PHF-tau, and activated microglia) in each treatment group, 
with high variance among groups and no significant differences across treatment 
groups.  Observations of mean counts suggest that fewer Aβ plaques were observed 
in Phase I treatment groups compared to treatment groups in Phases II and III.  Age 
could be responsible for this difference since the Phase I mice were 9-11 months of 
age, and consistent levels of Aβ were expected at 12 months of age for this colony of 
mice (personal communication, K. Duffy).  Additionally, since mice received a single 
dose prior to sacrifice, a 24-hour window was likely not long enough to allow for 
changes in protein levels resulting from insulin signaling alterations.  PGZ achieves 
steady-state serum concentrations within seven days, so the amount of PGZ after 24 
hours was likely not enough to significantly affect AD pathology in the model 
(National Institutes of Health, 2009).   
In addition, as the luminescence assays provided no observable sample, no 
further analysis was performed.  Therefore, no conclusions or observations about 
apoptosis could be made for any phase in this study.  
In Phase II, mice aged 15-17 months old were administered treatment daily 
for a period of three weeks, and were sacrificed 24 hours after the last administration. 
In Phase III, mice aged at 14 months were also dosed daily for three weeks, but 
pathology was assessed two weeks after the last administration of treatment.  These 
phases were designed to investigate the immediate and persistent effects of a longer-
term regimen of intranasal treatments on brain glucose metabolism and AD pathology 




Results of IHC did not show significant differences between Insulin and 
PGZ+Insulin treatment groups across Phase II and Phase III as hypothesized. 
However, there may be factors associated with experimental design and methodology 
that could have attributed to the lack of significant difference.  One main factor was 
small sample size, as having 5 mice per treatment group decreased likelihood of 
significant results.  Additionally, previous literature indicated that there should have 
been a significant difference in AD pathology when administering intranasal insulin 
(Liu et. al., 2013).  However, this was not seen in many of the results, suggesting that 
higher concentrations of insulin and PGZ may have been needed in order to see more 
significant effects.  Considering such limiting factors, further discussion points and 
proposed pathways were based on preliminary observations and trends seen in data in 
addition to any significant differences found in results.  
Due to loss of fluxomics data for Phases II and III, conclusions could not be 
drawn from Main Study samples.  Conclusions about glucose metabolism were drawn 
from Pilot Study data instead.  Increased glucose uptake from a PGZ+Insulin 
treatment was observed in non-transgenic mice in the Pilot Study; it was therefore 
expected that similar effects would be seen in 3x-Tg-AD mice in the Main 
Study.  This increase in glucose uptake would address the theory of AD as “Type III 
Diabetes.”  Insulin signaling is impaired in AD because of interference from Aβ 
oligomers and TNFα (Xie et al., 2002).  Insulin triggers signaling molecules in the 
ISP, especially IRS1.  With increased levels of IRS1, some downstream signaling is 
able to continue despite inference from TNFα, and more insulin is present to compete 




hypothesized that AD neurons are insulin resistant, the increase in glucose 
metabolism by PGZ+Insulin and sensitization of insulin signaling through activation 
of PPARγ would compensate for this decrease in glucose uptake.  PGZ stimulates 
both PPARγ and Akt to upregulate the translocation and transcription of GLUT4 
(Leonardini et al., 2009).  PPARγ also stimulates the Cbl/CAP complex to further 
increase the amount of GLUT4 (Monsalve et al., 2013).  Therefore, the otherwise 
declined rate of glucose uptake could be raised by PGZ+Insulin treatment sensitizing 
the ISP to insulin.  
The loss of glucose uptake in the AD brain could be more focused on insulin-
independent mechanisms like GLUT1 and GLUT3.  In this case, the treatment of 
PGZ+Insulin to GLUT4 would be compensating for the loss of glucose transport in 
other GLUTs, meaning that the treatment does not directly address the 
downregulation of GLUT1 and GLUT3 but still alleviates its effects through 
enhancing the contributory mechanism of GLUT4.  This suggests that if AD is in part 
caused by a decrease in glucose uptake, treatment with an insulin sensitizer can help 
alleviate its effects. 
In contrast, a different explanation of the increase in glucose uptake through 
PGZ+Insulin treatment could be that GLUT4 is a direct contributor to AD.  This 
would suggest that the ISP and GLUT4 could be a faulty pathway.  These proposed 
mechanisms could suggest that GLUT4 may play a more important role in AD 
pathology than previously understood.  This would also be supported by the 
discoveries of abundant GLUT4 mRNA in the subiculum and hippocampus, which 




Significant difference was found between Saline and PGZ+Insulin treatments 
groups in 6E10 data for Phase II.  Additionally, general trends in mean counts show 
lower amyloid deposition counts in the PGZ+Insulin group than in the Insulin group 
for Phase II, indicating that the addition of PGZ lowered pathology more than just 
Insulin when observed immediately after treatment.  This trend may be due to the 
effects of insulin and PGZ on IDE and ApoE.  The presence of insulin triggers IDE, 
which degrades Aβ plaques (Farris et al., 2003).  PGZ increases insulin’s effects by 
sensitizing the cell, and it increases ApoE proteins that degrade Aβ plaques.  The 
increased effect of PGZ on plaque amelioration may also be due to the drug’s 
downregulation of the BACE1 enzyme that improperly cleaves APP and creates Aβ 
oligomers (Liu et al., 2013). 
For Phase III 6E10 data, significant difference was found between Saline and 
PGZ+Insulin, similar to Phase II.  However, in contrast to Phase II, data trends 
showed very little difference in mean counts between PGZ+Insulin and Insulin.  This 
may suggest that the full effects of only insulin on Aβ plaques take longer to 
manifest, as Phase II saw a trend of decreased pathology in PGZ+Insulin compared to 
Insulin that was not observed in Phase III.  However, because mean counts between 
PGZ+Insulin and Insulin seemed to become level in Phase III, it would suggest that 
the additive effects of PGZ are useful for a more immediate decrease in plaque 
formation but not for consistently decreased pathology compared to only insulin in 
the long term.  
AT8 immunostaining for PHF-tau in both Phases II and III resulted in 




groups were expected to show a decline in pathology compared to the 
control.  Insulin dysfunction results in increased phosphorylation of tau by inhibiting 
phosphatase activity (Planel et al., 2007).  By restoring insulin signaling function, 
these effects were expected to subside.  Insulin was also predicted to decrease the 
amount of hyperphosphorylation by inhibiting GSK-3, a kinase that 
hyperphosphorylates tau (Blazquez, Velazquez, Hurtado-Carneiro & Ruiz-Albusac, 
2014).  PGZ was predicted to cause an even greater reduction in pathology because of 
PPARγ’s additional inhibitory effects on Cdk5 and JNK signaling. 
Results from Iba1 immunostaining showed statistically significant differences 
between Insulin and Saline, as well as between PGZ+Insulin and Saline, in Phase II. 
In Phase III, significant difference was found only between Saline and Insulin 
treatment groups. The Insulin group was expected to show decreased inflammation 
because insulin modulates the PI3K pathway responsible for inflammation and 
apoptosis in AD (Blazquez, Velazquez, Hurtado-Carneiro & Ruiz-Albusac, 2014). 
Insulin also inhibits GSK-3 activity, which stimulates the production of anti-
inflammatory cytokines and decreases the amount of inflammatory cytokines 
(Blazquez, Velazquez, Hurtado-Carneiro & Ruiz-Albusac, 2014).  PGZ was expected 
to have an effect on inflammation because the literature has shown that TZDs stop the 
transcription of AP-1 nuclear factor, thereby preventing microglial activation by Aβ 
plaques.   
While a luminescence assay was performed to measure caspases 3,7 and 9 
activity in Phase II and III, results were not interpretable due to samples in each phase 




concentration of sample used in each well or a contaminated control well. Further 





Chapter 7: Conclusion 
AD has long been associated with complications in glucose metabolism. This 
study attempted to use PGZ in conjunction with insulin in order to activate PPARγ 
and upregulate insulin receptors in order to increase glucose metabolism and decrease 
AD pathology (Figures 20 and 21).  Insulin and PGZ+Insulin treatments were 
administered intranasally to 3x-Tg-AD mice in order to bypass the BBB and directly 
target treatment to the brain.  Post-mortem analysis was performed in order to 
measure effects of treatment on brain glucose metabolism, Aβ plaques, NFTs, 
inflammation, and apoptosis.  Pilot Study results indicated increase in glucose 
metabolism according to increasing doses of PGZ+Insulin, suggesting that the 
treatment would increase brain glucose metabolism in a 3x-Tg-AD mouse.  While 
results were generally insignificant across post-mortem tests between PGZ+Insulin 
and Insulin treatments in the Main Study, general trends from Aβ deposition 
immunostaining may suggest that the addition of PGZ to insulin treatments would 
increase immediate effects on AD pathology, but would not enhance the effects of 
insulin treatments on AD pathology in the longer term.  Thus, trends from the study 
and proposed biochemical pathways suggest that an intranasal PGZ+Insulin treatment 
could increase glucose metabolism and decrease pathology in an AD affected 
brain.  Therefore, future research should continue to investigate the roles of TZDs and 
the ISP, especially through the use of intranasal administration of TZDs, in order to 





Figure 20. The Proposed Mechanisms by which the Insulin Treatment Ameliorates 
AD Pathology. Decreased apoptosis and hyperphosphorylated tau was not observed 
in this study (grey). Insulin was shown to have an effect on inflammation, Aβ plaques, 
and glucose uptake (blue). Figure modified from Perez & Quintanilla, 2015; De 
Felice, Lourenco, & Ferreira, 2014; Blazquez, Velazquez, Hurtado-Carneiro & Ruiz-
Albusac, 2014; Farris et al., 2003; Leibiger, Leibiger & Berrggren, 2008.  Created by 






Figure 21. The Proposed Mechanisms by which the TZD Treatment Ameliorates 
AD Pathology.  Decreased apoptosis and hyperphosphorylated tau were not 
observed in this study, and mitochondria function and neuroplasticity was not 
investigated (grey).  PGZ+Insulin was shown to have an additive effect over insulin 
treatment to reduce Aβ plaques and increase glucose uptake (blue). Information 
from: Perez & Quintanilla, 2015 and Blazquez, Velazquez, Hurtado-Carneiro & Ruiz-
Albusac, 2014.  Created by A. Zachery.   
 
7.1  Future Directions 
The present study aimed to utilize the intranasal administration of PGZ in 
order to investigate the ISP in AD. Many of the results from the study were 
inconclusive or influenced by limiting factors and confounding variables. Further 




more replicable data, robust results, and clearer insights into the role of the ISP and 
AD pathology. 
As some of the techniques used were novel, future studies can aim to refine 
the methods used in this study.  The largest obstacle of the present study was using 
the intranasal technique to administer PGZ, as there was no precedent in previous 
literature on standard dosing concentrations or solution preparation.  Thus, it was 
challenging to discern if the results were caused by the effects of PGZ, or if the dose 
of PGZ was not high enough to see change.  Future studies should aim to establish a 
standard protocol of the intranasal administration of PGZ in order to evaluate its 
effects on AD more vigorously. 
Another obstacle faced in the present study was confounding variables across 
phases, which future studies should aim to reduce or eliminate.  One of these 
confounding variables was the difference in mouse ages across study cohorts.  For 
this study, it was not possible to compare results across phases, as each age group 
showed different levels of onset of AD pathology at the time of the treatment 
regimen.  Future studies should isolate one age group across the entire study, or study 
the effects of an insulin and PGZ regimen across different age groups in order to 
evaluate the role of onset and level of pathology on the treatment.  Another 
confounding variable was that during the dosing period, multiple researchers handled 
mice.  This exposed the mice to varied durations of dosing and varied physical 
handling, which could have caused behavioral effects as well as effects on 
pathology.  Finally, different GC-MS machines were used during fluxomics analysis 




affected the resulting fluxomics data.  Future experimental designs should aim to 
reduce such confounding variables. 
 In addition to changes in methodology, future studies could explore further 
theoretical designs of the present study to gain more information on the role of TZDs 
and the ISP on AD.  For example, there are differences between the TZDs, PGZ and 
RGZ, and future studies could investigate the varying effects on AD 
pathology.  Studies in the future could also conduct behavioral tests on animal models 
receiving a TZD and insulin regimen in order to investigate how changes in 
pathology translate into changes in observable behavior and memory.  Additionally, it 
could be investigated whether the administration of a TZD alone, without 
combination with insulin, would affect AD pathology.  This could indicate whether 
administration of TZDs coupled with insulin does in fact have an additive effect in 
comparison to administration of insulin or TZDs alone.  Finally, studies could 
implement different time points than the present study to evaluate even longer term 
effects of a TZD and insulin regimen than the three weeks used in the current study.  
Performing future studies that address these different aspects can help further 
investigate the role of TZDs and the ISP on AD pathology in efforts to continue 




























Figure 22. Glucose Metabolism.  Fluxomics analysis was used to determine the ratio 
of 13C labeled glucose as an indicator of glucose metabolism.  The higher ratio 
following 60 mg PGZ indicates this dose was most effective in elevating glucose 





Appendix B: Animal Care Training  
All team members working with mice underwent the Animal Handler 
Training course given by Dr. Douglas Powell, a University of Maryland attending 
veterinarian.  Dr. Angela Black, an ANSC veterinarian, also trained team members in 
proper handling technique and husbandry as required by the IACUC protocol 
(National Academy of Sciences, 2011).  Tikina Smith, a Lab Animal Technologist at 
the UMD Central Animal Resource Facility (CARF), assisted team members in 
practice of the intranasal grip.  Lastly, Dr. Brian Bequette trained team members in 
laboratory safety and proper handling of chemicals. 
Mice were housed in the University of Maryland Animal Sciences (ANSC) 
facility with controlled temperature and humidity (Council, 2011), and were exposed 
to 12-hour light and dark cycles to mirror the normal light cycles of rodents (Chu, Li 
& Praticò, 2013).  Mice were kept in plastic cages with stainless steel covers 
appropriate for their body weights of 20-35 g with generally 3-4 mice of the same 
treatment group in each (Searcy et al., 2012).  The mice were relocated accordingly if 
they were incompatible or aggressive.  Water and standard rodent chow (Envigo 
NIH-07 rodent diet) were provided ad libitium (B. Bequette, personal 
communication, December 2, 2013).  
In instances of dehydration, Lixit water bottles were replaced with standard 
water bottles, and mice were provided sterile water gel (HydroGel) by ANSC staff. 
Water bottles were monitored and refilled daily by ANSC staff.  Additionally, the 
ANSC facility experienced a pinworm outbreak during the study.  Mouse diet was 




Rodent Diet with fenbendazole 150 mg/kg) for a duration of nine weeks, after which 

























Appendix C: Intranasal Insulin Method  
 
 
Figure 23. Intranasal Grip.  Mice were held in the non-dominant hand with the 
thumb and middle finger gripping the scruff.  This immobilized the head. The mouse 
was angled upwards for ease of intranasal administration.  The Hamilton syringe was 
held in the dominant hand.   The handler administered small drops of the treatment to 
alternating nostrils.  
 
Mice were acclimated to the researchers’ handling and intranasal grip for two 
weeks prior to treatment to reduce stress on the mice.  The study began once the mice 
were acclimated.  Mice were taken out of the cage by the bases of their tails and 
placed on the cage top.  The mice gripped the top of the cage with their paws, which 
allowed the handler to stretch the mouse body slightly.  Then, the handler grasped the 




and middle finger.  Handlers took great care to make sure that the mice were not held 
too tightly, as respiratory function could be restricted.  Mice were then turned around 
onto their backs.  This immobilized the head to allowed for administration.  Mice 
were held with the non-dominant hand at a 45-degree angle with nostrils pointing 
upwards.  The required dose of solution was administered through slow drops in 
alternating nostrils using a Hamilton syringe.  Rate of drops was determined based on 
speed and ease of drop inhalation.  Time was taken between drops so the mice would 
not be overwhelmed.  Different syringes were used for Saline, Insulin, and 
PGZ+Insulin.  Syringes were thoroughly rinsed after each dosing session with 









Appendix D: In Depth Calculation of Intranasal PGZ Doses 
The dosage for PGZ was approximately 30.6 µg per intranasal injection. 
Traditionally, an adult human who is prescribed PGZ is prescribed a 30 mg tablet that 
contains approximately 25 mg of pure PGZ.  Because the brain is where 20% of 
glucose utilization occurs, this means that the body is in charge of 80% of glucose 
utilization.  The mass of the brain, in both humans and mice, is 2% of the total body 
mass, and to design the dosage, both the brain’s utilization of glucose as well as its 
mass proportion are relevant and must be compromised.  Therefore, the dosage given 
to the mice was 10% of what the entire body would require because the brain is being 
specifically targeted in this experiment.  Considering other factors such as the ratio of 
brain mass to body mass in both mice and humans, the surface area of the olfactory 
epithelium in both mice and humans, and the amount of liquid a mouse’s nose can 
hold, it is ultimately determined that an acceptable dose of PGZ for a mouse would be 
30.6 µg in a volume of 24 µL of acidic saline solution.  Twenty-four µL of acidic 
saline solution is chosen because it is the common volume of intranasal liquid 
administered to a mouse model (Stein-Streilein, Guffee & Fan, 1988).  Within these 
24 µL of acidic saline, 120 µg of insulin will also be dissolved (Renner et al., 
2012).  This mixture of PGZ and insulin in an acidic saline solution was given 
intranasally to the mice.  The drug on the market, known as “Actos,” is a pill of PGZ 
hydrochloride, and this study used a pure laboratory sample of it in powder 
form.  The powder was dissolved in 24 µL of acidic saline solution (Actos, 










Appendix E: Immunohistochemistry Protocols 
IHC is the application of both monoclonal and polyclonal antibodies to 
determine the tissue distribution of an antigen in relevant tissue (Duraiyan et al., 
2012).  It requires a brain biopsy, which is then incubated with the appropriate 
antibody and secondary antibody before being visualized with a dye.  IHC is 
especially useful in determining the pathology of diseases because it can determine 
the presence of a large number of proteins, enzymes, and tissue structures (Duraiyan 
et al., 2012).  
IHC helps to determine the progression of AD by measuring the presence of 
several markers.  The National Institute on Aging-Alzheimer’s Association Guidelines 
for the Neuropathic Assessment of Alzheimer’s Disease recommends that IHC be 
used specifically for the identification of Aβ plaques and PHF-tau tangles  (Montine 
et al., 2012).  Aβ plaque density, PHF-tau tangle density, inflammation, and apoptosis 
will be observed through IHC.  
Post-mortem analysis must be performed on sections of brain tissue to 
validate the existence and severity of AD pathology exhibited.  The presence of Aβ 
plaques and phosphorylated tau tangles are used to quantify the pathological 
progression of AD, making them important markers to analyze when determining the 
effects of treatments on the progression of AD.  Post-mortem testing is the primary 
means for collecting data about AD and the treatments used from the mouse brain 
samples.  In recent literature regarding post-mortem analysis of AD model mice, there 




analyze the tissue samples: IHC staining with 6E10, microglia, and tau tangle assays, 
caspase 3/7 and 9 assays, and fluxomics analysis.    
The 6E10 assay is a type of IHC procedure used to identify and quantify the 
amount of Aβ plaques present in an AD affected brain.   Comparison of the quantity 
of plaques present in brain samples can determine differences in AD pathology 
between the brain samples.  Brain samples stained with the 6E10 reagent are 
examined under a microscope and the amount of Aβ plaque present is quantified 
(Gupta et al., 2014).   
Tau antibody staining can be performed to identify NFTs. Because AD is 
characterized by the abnormal phosphorylation of normal tau proteins, the antibodies 
used in IHC need to specifically target the abnormal, disease-associated epitopes. 
Along with NFTs and PHF-tau, IHC usually also includes neurophil threads, 
dystrophic neurites, and diffuse “pre-tangle” tau accumulations (Castellani, Alexiev, 
Phillips, Perry & Smith, 2007). Again, this method of IHC using specific PHF-tau 
antibodies allow for the qualitative identification of the amount of phosphorylated tau 
tangles in brain sections, and thus gives further information on the AD pathology 
present in the brain samples. 
Microglia are major cellular mediators for inflammation. As previously 
mentioned, the inflammatory response is a key factor in the neuropathological 
features of AD.  Microglia are found in the ramified, or resting state, and the 
amoeboid, or activated, state. Previous research has shown increased activated 




Iba1 is a protein that is specifically expressed in macrophages and microglia, 
and is upregulated in the activation of those cells. Thus, the Iba1 antibody can be used 
as a marker for activated microglia activity. As per IHC procedures, the detection of 
the bound antibody will be evidenced by a colorimetric reaction. The fixed, sliced 
brain tissue can then be qualitatively identified for the Iba1 protein according to the 
colorimetric reaction, presenting information on the presence of activated microglia 











Appendix F: Fluxomics Protocol 
 
Adapted with the help of Leslie Juengst (Hachey et al., 1999).  
Brain Preparation: 
1. Place back half of left hemisphere of mouse brain in an Eppendorf tube 
2. Add 0.8 mL of 1:1 methanol-water mixture 
3. Homogenize at full speed 
4. Add 0.8 mL chloroform 
5. Mix on rotary mixer for 30 minutes 
6. Centrifuge for 5 minutes at 13,000 rpm 
7. Split aqueous supernatant into clean Eppendorf tube 
Preparation of IPAc Derivatives of Hexoses: 
1. Add 0.3 mL distilled water and 1 mL acetone 
2. Centrifuge for 5 minutes at 13,000 rpm 
3. Transfer to 4.0 mL Reacti-Vial 
4. Blow samples down under gentle stream (2 psi) of N2 gas with 50°C heat on 
Reacti-Therm until dry 
5. Add 1 mL 0.38 M Sulfuric Acid in acetone and cap 
6. Let stand at room temperature for 1 hour 
7. Transfer to screw cap culture tube 
8. Carefully neutralize with 2 mL 0.44 M Sodium Carbonate and vortex to mix 
9. Add 2 mL of saturated sodium chloride and vortex to mix 
10. Add 3 mL of ethyl acetate 




12. Let sample separate into layers 
13. Split supernatant into 4.0 mL Reacti-vial 
14. Blow down at room temperature under gentle stream (2 psi) of N2 gas until 
dry 
Acetylation of IPAc Derivatives of Hexoses: 
1. Acetylate by adding 100 µL of 1:1 ethyl acetate:acetic anhydride 
2. Cap and place on Reacti-Therm to heat at 60°C for 30 minutes 
Data Collection 
1. Transfer 125 µL of sample to GC tubes 








Appendix G: Caspase 3 and 9 
 
Caspases are cysteine-aspartic proteases. Proteases, which are enzymes that 
break down proteins, are involved in many physiological reactions in the body.  The 
primary role of caspases is to degrade other proteins.  One of the most important 
reactions regulated by proteases is the apoptosis signaling pathway (Lamkanfi & 
Kanneganti, 2010).  Apoptosis is an integral part of normal cellular function as 
detailed previously in the literature review.  Apoptosis can be analyzed by measuring 
caspase 3 and 9 activities (Elmore, 2007).  Caspase 9 is an initiator caspase, which 
means that it signals an effector caspase to degrade proteins.  Caspase 3 is an effector 
caspase that cleaves a large set of substrates and results in the characteristic 
hallmarks, both morphological and biochemical, of apoptosis.  These include 
phosphatidylserine exposure, nuclear condensation and genomic DNA fragmentation 
(Lamkanfi & Kanneganti, 2010).   
If samples are harvested at multiple time points, caspase assay results can 
provide considerable temporal and spatial information about caspase 
activation.  Caspase assays are simple to run as well. They are also efficient--one 
relatively small sample can have enough material for analysis of multiple activities 







All citations are from the Medline Plus dictionary, unless otherwise noted 
Medline Plus, (2012). Bethesda, MD: National Institutes of Health. 
 
Actos: the brand name for pioglitazone 
Agonist: a compound that can bind to a receptor not meant for it and start a reaction 
Allele: a form of a gene at a locus 
Alzheimer’s Disease (AD): named after German neurologist Alois Alzheimer, 
Alzheimer’s Disease is a disease in the late middle aged or old brain that 
causes memory loss and mood changes.  In late stages, it seriously impairs 
most functions and causes neuronal degeneration and plaques in the brain. 
Amyloid Precursor Protein (APP): a protein that, when cleaved, forms AB 
proteins* 
Amyloid-Beta (Aβ) Protein: a protein that is the main component of plaques in AD 
Amyloid: a protein mass deposited in organs and tissue under abnormal conditions 
like AD 
Anesthetization: the process of blocking pain impulses and neurons to the brain; 
done to prevent discomfort during surgery or other treatment 
Antibody: a protein in the immune system that is stimulated by an antigen and helps 
destroy it  
Antigen: a foreign substance in the body that can be attacked by the immune system 
                                                
 




Apolipoprotein E (APOE): a class of protein that makes a lipoprotein with a lipid 
Apoptosis: the process of programmed cell death (cell “suicide”) 
Assay: an analytical procedure that measures the presence or amount of a substance 
Atrophy: shrinking in size and function of a body part or structure 
Autosomal: characteristic of a chromosome other than a sex (X or Y) chromosome 
Aβ oligomer (AβO): small soluble Aβ* 
Aβ plaque: a lesion of brain tissue, usually in AD, made of mainly AB proteins and 
degenerating nerve cells 
Biomarker: a biological indicator of a condition or disease 
Blood Brain Barrier (BBB): a protective barrier between the brain and blood in the 
body and blocks access to the central nervous system by harmful molecules 
c-jun N-terminal kinase (JNK): a phosphorylating protein that plays a key role in 
apoptosis* 
Cascade: a biochemical process that occurs by a series of steps that each set off the 
next event 
Central Nervous System (CNS): the nerves inside the brain and spinal cord 
responsible for behavior 
Centrifuge: a machine that uses centrifugal force to separate substances with 
different densities 
Cognitive function: conscious intellectual activity, like thinking and memory 
                                                
 





Cytochrome: any of several intracellular hemoprotein respiratory pigments that are 
enzymes functioning in electron transport as carriers of electrons 
Diabetes mellitus: a disease that can be hereditary or developed characterized by 
having low insulin levels or defective insulin, excessive amounts of urine, 
high blood sugar, and weight loss, hunger, and thirst 
Diabetes: a disease characterized by having excessive amounts of urine 
Differentiation: modification of unspecialized cells and tissues that leads to their 
final structure and function 
Dimer: two molecules that are combined to form a single compound 
Downstream insulin signaling pathway: the part of the insulin signaling pathway 
occurring after the initial insulin addition to the insulin receptor 
Extraneuronal pathway: signaling outside of a neuron 
Extrinsic: acting on the whole but originating from outside a part 
Familial: hereditary, inherited 
Gas chromatography: vaporized sample moves through a column and separates into 
component compounds 
Glucose metabolism: the breakdown of glucose into smaller usable parts, which 
releases energy 
Glycogen: the long-term storage form of glucose 
Hippocampus: a region of the brain that stores and processes memory 
Hydrophilicity: attraction to water 




Immunohistochemistry: the study of life and its chemicals through the lenses of 
immunology 
Immunoreactivity: reacting to particular antigens 
Immunostaining: staining a substance by using a stained antibody against it 
Insulin Receptor Substrate (IRS): a substance that bonds to an insulin receptor 
Insulin Receptor: the place where insulin binds to the cell 
Insulin Signaling Pathway (ISP): the process in which insulin allows glucose 
uptake* 
Insulin: a protein hormone made in the pancreas that facilitates glucose uptake into 
cells, regulating blood sugar. When there is not enough insulin present, 
diabetes is developed. 
Intranasal: entering through the nose 
Intrinsic: completely within a part and originating in the part 
Kinase: an enzyme that phosphorylates a substrate 
Limbic system: parts of the brain that deal with emotion and motivation (includes the 
hippocampus) 
Lipid: one of the main structural components of cells; fat; soluble in nonpolar organic 
solvents Luminescence: the low-temperature emission of light created by cellular 
processes  
Mild cognitive impairment (MCI): slight declines in conscious intellectual activity 
Nasal mucosa: a moist mucous membrane that lines the nasal cavity 
                                                
 




Neurofibrillary tangles: an accumulation of abnormally folded tau found in the 
cerebral cortex and hippocampus, especially in AD 
Neuron: a nerve cell that helps transmit signals through the nervous system 
Olfactory epithelium: the sheet of neurons lining the nasal cavity and associated 
with smell 
Oxidative stress: stress on the body from damage caused by excess free radicals  
PHF-Tau: phosphorylated tau (contains phosphate, PO43-) 
Peripheral: outside of the brain and CNS 
Peroxisome Proliferator-Activated Receptor (PPAR): transcription factor (protein 
that binds to DNA sequences to control gene expression) of genes that 
regulate lipid and glucose metabolism 
Phosphoinositide: a derivative of phosphatidic acid that is found in the brain and 
does not contain nitrogen  
Pioglitazone (PGZ): TZD in the hydrochloride form (C19H20N2O3S·HCl) 
Presenilin: a protein of cell membranes contributing to AD 
Protease: any enzyme that cuts proteins 
Proteolysis: the hydrolysis of peptides or proteins into simpler products 
Rosiglitazone (RGZ): TZD in the maleate form (C18H19N3O3S·C4H4O4) 
Saline: salt solution 
Secretase: a protease that cleaves APP into Aβ protein 
Sporadic: occurring randomly or singly 
Subiculum: a ventral extension of the hippocampus 




Tau: a protein in neurons that regulates their stability. Abnormal tau forms 
neurofibrillary tangles 
Thiazolidinedione (TZD): a treatment for diabetes mellitus type II which activates 
PPARγ 
Type II diabetes (T2D): diabetes mellitus that is developed by insulin receptor 
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